Glioblastoma remains a formidable brain tumor with limited effective treatments. Researchers have identified new therapeutic candidates such as MT-125, a compound that inhibits non-muscle myosin II, thereby impeding tumor invasion and sensitizing tumors to radiation and kinase inhibitors in preclinical models. Parallel studies reveal that modulation of gut microbiota can significantly enhance the efficacy of immunotherapies against glioblastoma, underscoring a novel axis of host-microbiome-tumor interactions. These findings pave the way for integrative treatment approaches combining targeted molecules and microbiome modulation.